ATAI (ATAI Life Sciences NV) Float Percentage Of Total Shares Outstanding : 79.38% (As of Apr. 26, 2025)

View and export this data going back to 2021. Start your Free Trial

What is ATAI Life Sciences NV Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, ATAI Life Sciences NV's float shares is 158.59 Mil. ATAI Life Sciences NV's total shares outstanding is 199.80 Mil. ATAI Life Sciences NV's float percentage of total shares outstanding is 79.38%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, ATAI Life Sciences NV's Insider Ownership is 0.44%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, ATAI Life Sciences NV's Institutional Ownership is 7.50%.

ATAI Life Sciences NV Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

ATAI Life Sciences NV's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	158.59	/	199.80
	=	79.38%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ATAI Life Sciences NV Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ATAI Life Sciences NV (NAS:ATAI) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

9VC:Germany

Address

Wallstrasse 16, Berlin, BB, DEU, 10179

Website

https://www.atai.life

ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.

Executives

Apeiron Investment Group Ltd.	10 percent owner	BLOCK A, APT.12, IL-PIAZZETTA, TOWER ROAD, SLIEMA O1 SLM1605
Srinivas Rao	officer: See Remarks	C/O ATAI LIFE SCIENCES N.V., 180 VARICK STREET, NEW YORK NY 10014
Sahil Kirpekar	officer: Chief Business Officer	C/O ATAI LIFE SCIENCES N.V., WALLSTRASSE 16, BERLIN 2M 10179
Anne Nagengast Johnson	officer: Chief Accounting Officer	C/O ATAI LIFE SCIENCES N.V., WALLSTRASSE 16, BERLIN 2M 10179
Florian Brand	officer: See Remarks	C/O ATAI LIFE SCIENCES N.V., 180 VARICK STREET, NEW YORK NY 10014
Stephen Bardin	officer: Chief Financial Officer	C/O ATAI LIFE SCIENCES N.V., KRAUSENSTRASSE 9-10, BERLIN 2M 10117
Gregory L Weaver	officer: Chief Financial Officer	185 BERRY STREET, SUITE 6504, SAN FRANCISCO CA 94107
Andrea Heslin Smiley	director	600 LEE ROAD, SUITE 100, WAYNE PA 19087
Michael Auerbach	director	158 HESTER STREET, APT 7F, NEW YORK NY 10013
Amir H Kalali	director	4350 EXECUTIVE DRIVE SUITE 325, SAN DIEGO CA 92121
Christian Angermayer	director, 10 percent owner	BLOCK A, APT.12, IL-PIAZZETTA, TOWER ROAD, SLIEMA O1 SLM1605
Rosnay Alexis De	director	C/O ATAI LIFE SCIENCES N.V., 180 VARICK STREET, NEW YORK NY 10014
Sabrina Martucci Johnson	director	11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Jason Camm	director	C/O ATAI LIFE SCIENCES N.V., 180 VARICK STREET, NEW YORK NY 10014
Presight Ii, Lp	10 percent owner	C/O ATAI LIFE SCIENCES N.V., 180 VARICK STREET, NEW YORK NY 10014